NCT00213980View on ClinicalTrials.gov

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Breast Cancer
Interventions
DRUG

Zoledronate

4 mg IV over 15 minutes administered once every 12 weeks times 4

Trial Locations (1)

53792

University of Wisconsin, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT00213980 - Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer | Biotech Hunter | Biotech Hunter